Le Lézard
Classified in: Health
Subject: PER

Healogics, Inc. Names Keith Koford as General Counsel


JACKSONVILLE, Fla., Jan. 17, 2019 /PRNewswire/ -- Healogics, the nation's largest provider of advanced chronic wound care services, today announced that Keith Koford has been appointed to serve as General Counsel. In this role, Koford will be responsible for the entire legal function of the organization, including implementing all strategic and tactical legal initiatives. He will also act as corporate secretary. Koford will report directly to Healogics Chief Executive Officer, David Bassin.

Keith Koford, Healogics General Counsel

"We are so pleased to welcome Keith to the Healogics team," said Bassin. "With his comprehensive business, compliance and legal knowledge, I am confident he will bring a valuable perspective to his new role. We are looking forward to seeing the contributions he will deliver throughout our company."

Koford joins Healogics with over 20 years of cumulative business and legal experience. In his most recent role, he served as Vice President, General Counsel for RTI Surgical, Inc. While there, Koford was the principal legal advisor and helped to develop and implement the company's comprehensive compliance program. Prior to his time at RTI, Koford was an attorney at Holland & Knight LLP, where he focused on the representation of U.S. and international-based healthcare, pharma/biotechnology and medical device companies. Before his legal career, Koford worked in the field of molecular biology at a genomics-based pharmaceutical development company. He has been named co-inventor on two biotechnology patent applications related to surgical procedures and is a co-author of the AdvaMed Code of Ethics on Interactions with Healthcare Professionals.

Koford received his Juris Doctor from the University of Florida and holds a Master of Business Administration from Massachusetts Institute of Technology (MIT Sloan School of Management).

About Healogics
Headquartered in Jacksonville, Fla., Healogics is the nation's wound healing expert. Last year over 330,000 patients received advanced wound care through a nationwide network of nearly 700 Wound Care Centers®.  The Healogics team is made up of almost 3,000 employees, 4,000 affiliated physicians and a Healogics Specialty Physician practice group of nearly 300. In addition to the company's network of outpatient Centers, Healogics partners with over 300 skilled nursing facilities to care for patients with chronic wounds and provides inpatient consults at more than 80 partner hospitals. As the industry leader, Healogics has the largest repository of chronic wound-specific patient data in the country. The Healogics Wound Science Initiative, an effort launched in 2017 to provide peer-reviewed research, recognizes the value and relevance of big data and advanced analytics to drive continuous, collaborative learning towards a better understanding of how to efficiently utilize healthcare resources for patients with wounds. For additional information, please visit Healogics.com.

SOURCE Healogics


These press releases may also interest you

at 03:00
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...



News published on and distributed by: